Zila starts phase III US trial for oral cancer test:
This article was originally published in Clinica
Executive Summary
Zila has begun a US phase III clinical trial of its oral cancer detection product, OraTest. The trial is expected to enrol less than 4,000 high-risk patients and is anticipated to be completed in a year, once all investigator sites are active. An interim analysis will be undertaken to determine the total number of patients required in the study. In a SEC filing this month, the Phoenix, Arizona firm said that upon the trial's completion, and assuming that the clinical endpoints have been met, it would take it around 3-6 months to prepare an OraTest marketing application for submission to the FDA. According to the American Dental Association, over 30,000 people are diagnosed with oral cancer annually in the US.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.